What Prothena Corp Public Ltd Co does.

Prothena Corporation plc (“Prothena” or the “Company”) is a late-stage clinical biotechnology company with expertise in protein dysregulation with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases.

Fueled by its deep scientific expertise built over decades of research, the Company is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. The Company’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including Parkinson’s disease, ATTR amyloidosis with cardiomyopathy, Alzheimer’s disease, Amyotrophic lateral sclerosis (ALS) and a number of other neurodegenerative diseases. Prothena is developing and applying its proprietary CYTOPE® technology to target a broad spectrum of intracellular disease pathways in the brain and periphery.

The Company was formed on September 26, 2012, under the laws of Ireland and re-registered as an Irish public limited company on October 25, 2012. The Company's ordinary shares began trading on The Nasdaq Global Market under the symbol “PRTA” on December 21, 2012, and currently trade on The Nasdaq Global Select Market.

Revenue and profit, by fiscal year.

More on PRTA.

• Prothena Corp Public Ltd Co summary
• Prothena Corp Public Ltd Co financial statements
• Prothena Corp Public Ltd Co key metrics
• Prothena Corp Public Ltd Co health scores and style box
• Prothena Corp Public Ltd Co earnings
• Prothena Corp Public Ltd Co dividends
• Prothena Corp Public Ltd Co valuation
• Prothena Corp Public Ltd Co ownership and insiders
• Prothena Corp Public Ltd Co peers

Figures from Prothena Corp Public Ltd Co's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.